Patent Application
20240076331
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jan. 28, 2022, is named 025471_WO016_SL.txt and is 501,203 bytes in size.
IL-10 is an anti-inflammatory cytokine. It inhibits cytokine (e.g., IFN-γ) production by Th1 cells via its action on antigen-presenting cell (APC) functions, including inhibition of cytokine production by activated macrophages and dendritic cells (Bogdan et al., J Exp Med. (1991) 174(6):1549-55; Fiorentino et. al., J Immunol. (1991) 146(10):3444-51; and Macatonia et al., J Immunol. (1993) 150(9):3755-65). IL-10 is also known to prevent antigen-specific proliferation of human T cells through inhibition of antigen-presenting capacity of monocytes via downregulation of class II MHC expression (de Waal Malefyt R et al., J Exp Med. (1991) 174(4):915-24).
Transforming growth factor β (TGF-β) is a key pleiotropic cytokine involved in controlling immune cell functions relating to both suppressive and inflammatory immune responses. TGF-β inhibits cytotoxic T lymphocyte (CTL), Th1-, and Th2-cell differentiation while promoting peripheral (p)Treg-, Th17-, Th9-, and Tfh-cell generation, and T-cell tissue residence in response to immune challenges (Sanjabi et al., Cold Spring Harb Perspect Biol. (2017) 9(6):a0222336).
Given that IL-10 and TGF-β have immune-suppressive activities, these cytokines may potentially form the basis of therapies for autoimmune and inflammation diseases (Wang et al., Cold Spring Harb Perspect Biol. (2019) 11(2):a028548; Worthington et al., Immunobiology (2012) 217(12):1259-65). However, these cytokines have been found to have short half-lives in vivo, have high toxicity, and lack specificity for immune cells or disease site selectivity. Thus, there is a need to develop novel IL-10 and TGF-β cytokine therapeutics that have longer half-lives, cause fewer adverse effects, and provide better target specificity.
The present disclosure provides a prodrug comprising a cytokine moiety, a masking moiety, and a carrier moiety, wherein the masking moiety binds to the cytokine moiety and inhibits a biological activity of the cytokine moiety, the cytokine moiety comprises an interleukin-10 (IL-10) agonist polypeptide or a transforming factor beta (TGF-β) agonist polypeptide and is fused to the carrier moiety or the masking moiety, the carrier moiety binds to an antigen expressed on the surface of an immune cell; wherein the immune cell expresses a receptor for the cytokine moiety; and the masking moiety is fused to the cytokine moiety or to the carrier moiety, optionally through a peptide linker.
In particular embodiments, the IL-10 agonist polypeptide comprises SEQ ID NO: 1, 2, or 3, or an amino acid sequence that is at least 90% identical to SEQ ID NO: 1, 2, or 3.
In some embodiments, the TGF-β is selected from a TGF-β1 agonist polypeptide, a TGF-β2 agonist polypeptide, and a TGF-β3 agonist polypeptide. In some embodiments, the cytokine moiety comprises a human TGF-β agonist polypeptide comprising SEQ ID NO: 7, or an amino acid sequence that is at least 90% identical to SEQ ID NO: 7.
In some embodiments, the cytokine moiety is fused to the carrier moiety directly or via a non-cleavable or cleavable peptide linker and the masking moiety is fused to the carrier moiety directly or via a non-cleavable or cleavable peptide linker. In other embodiments, the prodrug further comprises a second cytokine moiety fused to the C-terminus of the cytokine moiety. In additional embodiments, the prodrug further comprises a second masking moiety fused to the C-terminus of the masking moiety.
In some embodiments, the two cytokine moieties are separately fused to the carrier moiety through cleavable peptide linkers, wherein said cleavable linker comprises 4, 5, 6, 7, 8, 9, or 10 amino acids, optionally comprising SEQ ID NO: 77.
In some embodiments, the two cytokine moieties are separately fused to the carrier moiety directly or via non-cleavable peptide linkers and two masking moieties are separately fused to the two cytokine moieties directly or via non-cleavable or cleavable peptide linkers.
In some embodiments, two cytokine moieties are separately fused to the carrier moiety directly or via non-cleavable peptide linkers and one masking moiety is fused to one of the two cytokine moieties directly or via a non-cleavable or a cleavable peptide linker. In some embodiments, two masking moieties are separately fused to the carrier moiety directly or via non-cleavable peptide linkers and two cytokine moieties are separately fused to the two masking moieties directly or via non-cleavable peptide linkers.
In some embodiments, the cytokine moiety is fused to the carrier moiety directly or via a non-cleavable peptide linker and the masking moiety is fused to the carrier moiety directly or via a non-cleavable peptide linker, and a second cytokine moiety is fused to the C-terminus of the masking moiety directly or via a non-cleavable peptide linker.
In some embodiments, the carrier moiety comprises 1) an antibody or antigen-binding fragment thereof, or 2) an antibody Fc domain and two antigen-binding moieties, which are fused directly or via a non-cleavable peptide linker to the N-terminus or the C-terminus of the Fc domain. In some embodiments, the antibody or antigen-binding fragment thereof binds to an antigen expressed on the surface of an immune cell. In some embodiments, the immune cell is selected from an NK cell, a T cell, a B cell, and a macrophage and expresses a cell surface receptor for the cytokine moiety. In some embodiments, the Fc domain optionally comprises knobs-into-holes mutations. In some embodiments, the Fc domain or the Fc domain of the antibody optionally comprises RF mutations, wherein the RF mutations reduce or eliminate binding of the Fc domain to a protein A affinity resin. In some embodiments, the RF mutation is selected from H371R/Y372F (numbering according to SEQ ID NO: 107) or H453R/Y454F (numbering according to SEQ ID NO: 112).
In some embodiments, the carrier moiety comprises an antibody or antigen-binding fragment thereof that binds to an antigen selected from IL-1 receptor accessory protein (IL1RAP), IL-1 receptor (IL-1RI), a human IL-3 receptor, IL-4 receptor α chain (IL-4Rα), IL-5 receptor α chain (IL-5Rα), IL-6 receptor α chain (IL-6Rα), a human IL-9 receptor, a human IL-13 receptor, a human IL-17 receptor, a human IL-23 receptor, a human IL-31 receptor, a human IL-33 receptor, a receptor for thymic stromal lymphopoietin (TSLP), CD20, CD25, BCMA, CD40, CD80, CD86, Trem-1, CSF-1R, OX40, 4-1BB, TNF-alpha receptor 1 (TNFR-1), TNF-alpha receptor 1 (TNFR-2), a receptor for B lymphocyte stimulator (BLyS), mucosal addressin cell adhesion molecule 1 (MAdCAM-1), and an Interferon-alpha receptor.
In some embodiments, the carrier moiety comprises an antibody or antigen-binding fragment that comprises the same heavy and light chain complementarity-determining regions (CDRs), the same heavy and light variable domains, or the same heavy and light chains, as an antibody selected from canakinumab, adalimumab, CDP-571, infliximab, rontalizumab, sifalimumab, olokizumab (CDP6038), elsilimomab, BMS-945429 (ALD518), sirukumab (CNTO 136), levilimab (BCD-089), siltuximab, secukinumab, ixekizumab, ustekinuma, guselkumab, and tildrakizumab.
In some embodiments, the carrier moiety comprises an anti-IL-4 receptor α chain (IL-4Rα) antibody or an antigen-binding fragment thereof, which comprises light chain CDRs derived from SEQ ID NO: 11 and heavy chain CDRs derived from SEQ ID NO: 12; or a light chain variable domain with an amino acid sequence of SEQ ID NO: 13 or at least 95% identical thereto, and a heavy chain variable domain with an amino acid sequence of SEQ ID NO: 14 or at least 95% identical thereto.
In some embodiments, the carrier moiety comprises an anti-IL-5 receptor α chain (IL-5Rα) antibody or an antigen-binding fragment thereof, which comprises a light chain variable domain with an amino acid sequence of SEQ ID NO: 15 or at least 95% identical thereto, and a heavy chain variable domain with an amino acid sequence of SEQ ID NO: 16 or at least 95% identical thereto.
In some embodiments, the carrier moiety comprises an anti-IL-6 receptor α chain (IL-6Rα) antibody or a binding fragment thereof, which comprises a light chain variable domain with an amino acid sequence of SEQ ID NO: 17 or at least 95% identical thereto, and a heavy chain variable domain with an amino acid sequence of SEQ ID NO: 18 or at least 95% identical thereto; or a light chain variable domain with an amino acid sequence of SEQ ID NO: 19 or at least 95% identical thereto, and a heavy chain variable domain with an amino acid sequence of SEQ ID NO: 19 or at least 95% identical thereto.
In some embodiments, the carrier moiety comprises an anti-Trem-1 antibody or a fragment thereof, which comprises a light chain variable domain with an amino acid sequence of SEQ ID NO: 21 or at least 95% identical thereto, and a heavy chain variable domain with an amino acid sequence of SEQ ID NO: 22 or at least 95% identical thereto.
In some embodiments, the carrier moiety comprises an anti-CD86 antibody or a fragment thereof, which comprises a light chain variable domain with an amino acid sequence of SEQ ID NO: 23 or at least 95% identical thereto, and a heavy chain variable domain with an amino acid sequence of SEQ ID NO: 24 or at least 95% identical thereto.
In some embodiments, the carrier moiety comprises an extracellular domain of CTLA-4 (CTLA-4-ECD) or a functional analog thereof, which comprises an amino acid sequence of SEQ ID NO: 25 or 61 or at least 95% identical as that of SEQ ID NO: 25 or 61.
In some embodiments, the carrier moiety comprises an anti-interferon alpha receptor 1 (IFNRA-1) antibody or antigen-binding fragment thereof, which comprises a light chain variable domain with an amino acid sequence of SEQ ID NO: 52 or at least 95% identical as that of SEQ ID NO: 52, and a heavy chain variable domain with an amino acid sequence of SEQ ID NO: 51 or at least 95% identical as that of SEQ ID NO: 51.
In some embodiments, the carrier moiety comprises an anti-CD86 antibody or a fragment thereof, which comprises a light chain variable domain with an amino acid sequence of SEQ ID NO: 23 or at least 95% identical thereto, and a heavy chain variable domain with an amino acid sequence of SEQ ID NO: 24 or at least 95% identical thereto.
In some embodiments, the peptide linker that is cleavable by one or more proteases located at a site of inflammation or an autoimmune disease, optionally selected comprising a substrate sequence of urokinase-type plasminogen activator (uPA), matrix metallopeptidase (MT1-MMP), matrix metallopeptidase 2 (MMP2), MMP3, MMP9, matriptase, legumain, plasmin, TMPRSS-3/4, cathepsin, caspase, human neutrophil elastase, beta-secretase, or PSA, or (i) both uPA and MMP2, (ii) both uPA and MMP9, or (iii) matriptase, MMP2 and MMP9.
In some embodiments, the cleavable peptide linker is cleavable by one or more proteases located at a site of inflammation or an autoimmune disease.
In some embodiments, the non-cleavable peptide linker comprises an amino acid sequence selected from SEQ ID NOs: 95-99.
In some embodiments, the masking moiety inhibits the binding of the cytokine moiety to its receptor on the surface of a cell.
In some embodiments, the masking moiety comprises an extracellular domain of IL-10 receptor α chain (IL-10Rα-ECD), an analog of IL-10Rα-ECD, or an antibody against human IL-10 or a binding fragment thereof, or SEQ ID NO: 4, 5, or 6, or an amino acid sequence that is at least 95% identical thereto.
In some embodiments, the masking moiety comprises an extracellular domain of TGF-β Receptor II (TGFRII-ECD), an analog of TGFRII-ECD, or an antibody against human TGF-β or a binding fragment thereof.
In particular embodiments, the masking moiety comprises an extracellular domain of TGF-β Receptor II (TGFRII-ECD), an analog of TGFRII-ECD, or an antibody against human TGF-β or a binding fragment thereof, SEQ ID NO: 10, or an amino acid sequence that is at least 95% identical thereto, or a scFv that binds to human TGF-β, optionally wherein the scFv comprises a VH domain with an amino acid sequence of SEQ ID NO: 9 or at least 95% identical thereto, and a VL domain with an amino acid sequence of SEQ ID NO: 8 or at least 95% identical thereto.
In particular embodiments, the prodrug comprises two identical light chains and a first heavy chain polypeptide chain and a second heavy chain polypeptide chain, wherein the light chain comprises SEQ ID NO: 26 or an amino acid sequence at least 95% identical thereto the first heavy chain polypeptide chain comprises SEQ ID NO: 27 or 28, or an amino acid sequence at least 95% identical thereto, and the second heavy chain polypeptide chain comprises SEQ ID NO: 29 or 30, or an amino acid sequence at least 95% identical thereto.
In particular embodiments, the prodrug comprises two identical light chains and two identical heavy chains; wherein the light chain comprises SEQ ID NO: 26 or an amino acid sequence at least 95% identical thereto, and the heavy chain comprises SEQ ID NO: 31, 32, 33, 34, or 100 or an amino acid sequence at least 95% identical thereto.
In particular embodiments, the prodrug comprises two identical light chains and a first heavy chain polypeptide chain and a second heavy chain polypeptide chain; wherein the light chain comprises SEQ ID NO: 35 or an amino acid sequence at least 95% identical thereto the first heavy chain polypeptide chain comprises SEQ ID NO: 36 or an amino acid sequence at least 95% identical thereto, and the second heavy chain polypeptide chain comprises SEQ ID NO: 37 or 38, or an amino acid sequence at least 95% identical there.
In particular embodiments, the prodrug comprises two identical light chains and two identical heavy chains, wherein the light chain comprises SEQ ID NO: 35 or an amino acid sequence at least 95% identical thereto, and the heavy chain comprises SEQ ID NO: 39, 40, 41 or 42, or an amino acid sequence at least 95% identical thereto.
In particular embodiments, the prodrug comprises two identical light chains and a first heavy chain polypeptide chain and a second heavy chain polypeptide chain, wherein the light chain comprises SEQ ID NO: 43 or an amino acid sequence at least 95% identical thereto SEQ ID NO: 43, the first heavy chain polypeptide chain comprises SEQ ID NO: 44 or an amino acid sequence at least 95% identical thereto, and the second heavy chain polypeptide chain comprises SEQ ID NO: 45 or 46, or an amino acid sequence at least 95% identical thereto.
In particular embodiments, the prodrug comprises two identical light chains and two identical heavy chains, wherein the light chain comprises SEQ ID NO: 43 or said at least 95% identical thereto, and the heavy chain comprises SEQ ID NO: 47, 48, 49 or 50, or an amino acid sequence at least 95% identical thereto.
In particular embodiments, the prodrug comprises two identical light chains and a first heavy chain polypeptide chain and a second heavy chain polypeptide chain, the light chain comprises SEQ ID NO: 53 or an amino acid sequence at least 95% identical thereto, the first heavy chain polypeptide chain comprises SEQ ID NO: 54 or an amino acid sequence at least 95% identical thereto, and the second heavy chain polypeptide chain comprises SEQ ID NO: 55 or 56, or an amino acid sequence at least 95% identical thereto.
In particular embodiments, the prodrug comprises two identical light chains and two identical heavy chains, wherein the light chain comprises SEQ ID NO: 53 or an amino acid sequence at least 95% identical thereto, and the heavy chain comprises SEQ ID NO: 57, 58, 59 or 60, or an amino acid sequence at least 95% identical thereto.
In particular embodiments, the prodrug comprises two identical polypeptide chains comprising an amino acid sequence selected from SEQ ID NOs: 66, 67, 68, 69, 101-106 or at least 95% identical thereto.
In particular embodiments, the prodrug comprises a first polypeptide chain and a second polypeptide chain which form a heterodimer, wherein the first polypeptide chain comprises SEQ ID NO: 63 or 107, or an amino acid sequence at least 95% identical thereto, and the second polypeptide chain comprises SEQ ID NO: 64, 65, 105, or 106, or an amino acid sequence at least 95% identical thereto.
In particular embodiments, the prodrug comprises a first polypeptide chain and a second polypeptide chain which form a heterodimer; wherein the first polypeptide chain comprises SEQ ID NO: 107 or an amino acid sequence at least 95% identical thereto, and the second polypeptide chain comprises SEQ ID NO:105 or 106, or an amino acid sequence at least 95% identical thereto.
In particular embodiments, the prodrug comprises two identical light chains and two identical heavy chains, wherein the light chain comprises SEQ ID NO: 108 or an amino acid sequence at least 95% identical thereto SEQ ID NO: 108, and the heavy chain comprises SEQ ID NO: 109, 110, 111, or 113, or an amino acid sequence at least 95% identical thereto.
In particular embodiments, the prodrug comprises two identical light chains, a first heavy chain polypeptide chain, and a second heavy chain polypeptide chain, wherein the light chain comprises SEQ ID NO: 108 or an amino acid sequence at least 95% identical thereto, the first heavy chain polypeptide chain comprises SEQ ID NO: 110, or 111, or an amino acid sequence at least 95% identical thereto, and the second heavy chain polypeptide chain comprises SEQ ID NO: 112, or an amino acid sequence at least 95% identical thereto.
In particular embodiments, the prodrug comprises two identical light chains and two identical heavy chains, wherein the light chain comprises SEQ ID NO: 116, or an amino acid sequence at least 95% identical thereto, and the heavy chain polypeptide chain comprises SEQ ID NO: 114 or 115, or an amino acid sequence at least 95% identical thereto.
In some embodiments, the prodrug has a higher activity modulating an immune cell which expresses both the antigen targeted by the carrier moiety and a receptor for IL-10 or TGF-β than an immune cell which does not express both or either of the antigen and the cytokine receptor.
In other aspects, the present disclosure also provides a prodrug comprising pharmaceutical composition and a pharmaceutically acceptable excipient; a polynucleotide or polynucleotides encoding the prodrug; an expression vector or vectors comprising the polynucleotide or polynucleotides; and a host cell comprising the vector(s), wherein the host cell may be a prokaryotic cell or an eukaryotic cell such as a mammalian cell. In some embodiments, the mammalian host cell has the gene or genes encoding uPA, MMP3, MMP-2 and/or MMP-9 knocked out (e.g., containing null mutations of one or more of these genes).
In some embodiments, the present disclosure also provides a method of making the prodrug, comprising culturing the host cell under conditions that allow expression of the prodrug, wherein the host cell is a mammalian cell, and isolating the prodrug.
The present disclosure also provides a method of treating an autoimmune disease or inflammatory condition in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the prodrug or pharmaceutical composition of the present disclosure. The patient may have, for example, asthma, atopic dermatitis, Type I diabetes, diabetic ulcers, allergy, psoriasis, rheumatoid arthritis, multiple sclerosis, osteoarthritis, graft vs host disease (GvHD), lupus nephritis, systemic lupus erythematosus (SLE), Alzheimer's disease, a neuron degeneration disease, an inflammatory bowel disease, ulcerative colitis, Crohn's disease NASH, atherosclerosis, and systemic sclerosis.
Also provided herein are a prodrugs or pharmaceutical compositions for use in treating an autoimmune disease or inflammatory condition in a patient in need thereof; use of a prodrug for the manufacture of a medicament for treating an autoimmune disease or inflammatory condition in a patient in need thereof; and articles of manufacture (e.g., kits) comprising one or more dosing units of the present prodrug. In some embodiments, the present prodrug can be further combined with another therapeutic, such as a pharmaceutical composition comprising an IL-2 mutein, an antagonist of TNFα, an antagonist of IL-12, an antagonist of IL-17 or its receptor, an antagonist of IL-23 or its receptor, an antagonist of IL-6 or its receptor, an antagonist of IL-5 or its receptor, an antagonist of IL-4 or its receptor, an antagonist of IL-1β or its receptor, an antagonist of interferon alpha receptor-1 (INFAR-1), an antagonist of CD40, an antagonist of CD80, or an antagonist of CD86.
Other features, objects, and advantages of the invention are apparent in the detailed description that follows. It should be understood, however, that the detailed description, while indicating embodiments and aspects of the invention, is given by way of illustration only, not limitation. Various changes and modification within the scope of the invention will become apparent to those skilled in the art from the detailed description.
As used herein and in the appended claims, the singular forms “a,” “or,” and “the” include plural referents unless the context clearly dictates otherwise. Reference to “about” a value or parameter herein includes (and describes) variations that are directed to that value or parameter per se. For example, description referring to “about X” includes description of “X.” Additionally, use of “about” preceding any series of numbers includes “about” each of the recited numbers in that series. For example, description referring to “about X, Y, or Z” is intended to describe “about X, about Y, or about Z.”
The term “antigen-binding moiety” refers to a polypeptide or a set of interacting polypeptides that specifically bind to an antigen, and includes, but is not limited to, an antibody (e.g., a monoclonal antibody, polyclonal antibody, a multi-specific antibody, a dual specific or bispecific antibody, an anti-idiotypic antibody, or a bifunctional hybrid antibody) or an antigen-binding fragment thereof (e.g., a Fab, a Fab′, a F(ab′)2, a Fv, a disulfide linked Fv, a scFv, a single domain antibody (dAb), or a diabody), a single chain antibody, and an Fc-containing polypeptide such as an immunoadhesin. In some embodiments, the antibody may be of any heavy chain isotype (e.g., IgG, IgA, IgM, IgE, or IgD) or subtype (e.g., IgG1, IgG2, IgG3, or IgG4). In some embodiments, the antibody may be of any light chain isotype (e.g., kappa or lambda). The antibody may be human, non-human (e.g., from mouse, rat, rabbit, goat, or another non-human animal), chimeric (e.g., with a non-human variable region and a human constant region), or humanized (e.g., with non-human CDRs and human framework and constant regions). In some embodiments, the antibody is a derivatized antibody.
The terms “cytokine agonist polypeptide” or “cytokine moiety” refers to a wildtype cytokine, or an analog thereof. An analog of a wildtype cytokine has the same biological specificity (e.g., binding to the same receptor(s) and activating the same target cells) as the wildtype cytokine, although the activity level of the analog may be different from that of the wildtype cytokine. The analog may be, for example, a mutein (i.e., mutated polypeptide) of the wildtype cytokine, and may comprise at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten mutations relative to the wildtype cytokine.
The term “cytokine mask” or “masking moiety” refers to a moiety (e.g., a polypeptide) that binds to a cytokine, thereby inhibiting the cytokine from binding to its receptor on the surface of a target cell and/or exerting its biological functions while being bound by the mask. Examples of a cytokine mask include, without limitations, a polypeptide derived from an extracellular domain of the cytokine's natural receptor that makes contact with the cytokine.
The term “effective amount” or “therapeutically effective amount” refers to an amount of a compound or composition sufficient to treat a specified disorder, condition, or disease, such as ameliorate, palliate, lessen, and/or delay one or more of its symptoms.
The term “functional analog” refers to a molecule that has the same biological specificity (e.g., binding to the same ligand) and/or activity (e.g., activating or inhibiting a target cell) as a reference molecule.
The term “fused” or “fusion” in reference to two polypeptide sequences refers to the joining of the two polypeptide sequences through a backbone peptide bond. Two polypeptides may be fused directly or through a peptide linker that is one or more amino acids long. A fusion polypeptide may be made by recombinant technology from a coding sequence containing the respective coding sequences for the two fusion partners, with or without a coding sequence for a peptide linker in between. In some embodiments, fusion encompasses chemical conjugation.
The term “pharmaceutically acceptable excipient” when used to refer to an ingredient in a composition means that the excipient is suitable for administration to a treatment subject, including a human subject, without undue deleterious side effects to the subject and without affecting the biological activity of the active pharmaceutical ingredient (API).
The term “subject” refers to a mammal and includes, but is not limited to, a human, a pet (e.g., a canine or a feline), a farm animal (e.g., cattle or horse), a rodent, or a primate.
As used herein, “treatment” or “treating” is an approach for obtaining beneficial or desired clinical results. Beneficial or desired clinical results include, but are not limited to, one or more of the following: alleviating one or more symptoms resulting from a disease, diminishing the extent of a disease, ameliorating a disease state, stabilizing a disease (e.g., preventing or delaying the worsening or progression of the disease), preventing or delaying the spread (e.g., metastasis) of a disease, preventing or delaying the recurrence of a disease, providing partial or total remission of a disease, decreasing the dose of one or more other medications required to treat a disease, increasing the patient's quality of life, and/or prolonging survival. The methods of the present disclosure contemplate any one or more of these aspects of treatment.
It is to be understood that one, some or all of the properties of the various embodiments described herein may be combined to form other embodiments of the present invention. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described thereunder.
The present disclosure provides chimeric molecules or cytokine prodrugs that are useful to treat an autoimmune disease or an inflammation condition of a patient. In some embodiments, the cytokine prodrugs comprise a cytokine moiety, a masking moiety, a carrier moiety, and one or more peptide linkers. The terms “chimeric molecules” and “cytokine prodrugs” or “prodrugs” may be used interchangeably herein, with the exception that chimeric molecules may also include prodrug molecules following activation (i.e., after cleavage of one or more masking moieties).
In some embodiments, the cytokine moiety comprises an IL-10 agonist polypeptide or a TGF-β agonist polypeptide. In some embodiments, the carrier moiety comprises an Fc domain. In some embodiments, the carrier moiety comprises an antibody, or an antibody Fc domain with two antigen-binding moieties. In some embodiments, the masking moiety comprises an extracellular domain of IL-10 receptor alpha chain (IL-10Rα-ECD), a scFv, or Fab which binds to human IL-10. In some embodiments, the masking moiety comprises an extracellular domain of TGF-β Receptor II (TGFRII-ECD), a scFv, or Fab which binds to TGF-β. In some embodiments, the prodrug comprises one or more peptide linkers, which can optionally be non-cleavable or cleavable.
A. Cytokine Moieties of the Prodrugs
In some embodiments, the cytokine moiety comprises an IL-10 agonist polypeptide or a TGF-β agonist polypeptide. In some embodiments, the IL-10 agonist polypeptide comprises an amino acid sequence of SEQ ID NO: 1 or 2 or at least 90% identical as that of SEQ ID NO: 1 or 2. In a particular embodiment, the IL-10 agonist polypeptide comprises a F111S mutation (numbering according to SEQ ID NO: 1). In another particular embodiment, the IL-10 agonist polypeptide comprises an amino acid sequence of SEQ ID NO: 3.
In some embodiments, the cytokine moiety comprises TGF-β and the masking moiety binds to human TGF-β1. In some embodiments, the cytokine comprises an amino acid sequence of SEQ ID NO: 7, or at least 90% identical to SEQ ID NO: 7. In some embodiments, the masking moiety comprises an amino acid sequence of SEQ ID NO: 10, or at least 90% identical to SEQ ID NO: 10. In some embodiments, the masking moiety comprises a VH domain with an amino acid sequence of SEQ ID NO: 9 or at least 90% identical to SEQ ID NO: 9, and a VL domain with an amino acid sequence of SEQ ID NO: 8 or at least 90% identical to SEQ ID NO: 8.
B. Masking Moieties of the Prodrugs
The masking moiety in the present prodrugs may comprise a peptide, an antibody, or antibody fragment that binds to the cytokine moiety in the prodrug, thereby masking the cytokine moiety and inhibiting its biological functions. In some embodiments, the masking moiety is operationally linked to the rest of the prodrug through a peptide linker (cleavable or non-cleavable).
By way of example, the prodrug comprises an IL-10 or TGF-β agonist polypeptide and the masking moiety comprises a peptide, or an antibody, or antibody fragment that binds IL-10 or TGF-β and interferes with the binding of the IL-10 or TGF-β to its cognate receptors. In some embodiments, the masking moiety reduces biological activities of the IL-10 or TGF-β moiety while masked.
In some embodiments, the masking moiety comprises an extracellular domain of IL-10 receptor α chain (IL-10Rα-ECD), an analog of IL-10Rα-ECD, or an antibody against human IL-10 or a binding fragment thereof. In some embodiments, the masking moiety comprises an amino acid sequence of SEQ ID NO: 4, 5, or 6, or at least 95% identical as SEQ ID NO: 4, 5, or 6.
In some embodiments, the masking moiety comprises a scFv or Fab which binds to human IL-10. In some embodiments, the masking moiety comprises a scFv with an amino acid sequence of SEQ ID NO: 4 or 5 or at least 90% identical to SEQ ID NO: 4 or 5. In some embodiments, the masking moiety binds to human IL-10. In some embodiments, the masking moiety optionally comprises the extracellular domain of IL-10, which comprises an amino acid sequence of SEQ ID NO: 6 or at least 90% identical as that of SEQ ID NO: 6.
In some embodiments, the masking moiety comprises an extracellular domain of TGF-β Receptor II (TGFRII-ECD), an analog of TGFRII-ECD, or an antibody against human TGF-β or a binding fragment thereof. In some embodiments, the masking moiety is a scFv which binds to human TGF-β, wherein the scFv comprises a VH domain with an amino acid sequence of SEQ ID NO: 9 or at least 95% identical to SEQ ID NO: 9, and a VL domain with an amino acid sequence of SEQ ID NO: 8 or at least 95% identical to SEQ ID NO: 8.
In some embodiments, the IL-10 masking moiety comprises a peptide identified through a peptide library screening.
C. Carrier Moieties of the Prodrugs
The carrier moieties of the present prodrugs may be an antigen-binding moiety, or a moiety that is not antigen-binding. The carrier moiety may improve the PK profiles, such as serum half-life, of the cytokine agonist polypeptide and may also target the cytokine agonist polypeptide to a target site in the body, such as a disease site.
1. Antigen-Binding Domains of Carrier Moieties
The carrier moiety comprises an antigen-binding domain and may be an antibody or an antigen-binding fragment thereof, or an immunoadhesin. In some embodiments, the antigen-binding carrier moiety is a full-length antibody with two heavy chains and two light chains, a Fab fragment, a Fab′ fragment, a F(ab′)2 fragment, a Fv fragment, a disulfide linked Fv fragment, a single domain antibody, a nanobody, or a single-chain variable fragment (scFv). In some embodiments, the antigen-binding moiety is a bispecific antigen-binding moiety and can bind to two different antigens or two different epitopes on the same antigen. In some embodiments, the carrier moiety comprises two antigen-binding domains that share the same antigen specificity. The antigen-binding moiety may provide additional and potentially synergetic therapeutic efficacy to the cytokine agonist polypeptide.
The cytokine agonist polypeptide and its mask may be fused to the N-terminus or C-terminus of the light chain(s) and/or heavy chain(s) of the antigen-binding moiety. By way of example, the IL-10 or TGF-β agonist polypeptide and its mask may be fused to the antibody heavy chain or an antigen-binding fragment thereof or to the antibody light chain or an antigen-binding fragment thereof. In some embodiments, one terminus of the IL-10 or TGF-β agonist polypeptide is fused to the C-terminus of one or both heavy chains of an antibody, and the IL-10 mask is fused to the other terminus of the IL-10 or TGF-β agonist polypeptide through a non-cleavable peptide linker. In some embodiments, the IL-10 or TGF-β agonist polypeptide is fused to the C-terminus of one of the heavy chains of an antibody, and the IL-10 or TGF-β mask is fused to the C-terminus of the other heavy chain of the antibody through a non-cleavable peptide linker, wherein the two heavy chains contain mutations that allow the specific pairing of the two different heavy chains.
Strategies for forming heterodimers for Fc-fusion polypeptides or bispecific antibodies are well known (see, e.g., Spies et al., Mol Imm. (2015) 67(2)(A):95-106). For example, the two heavy chain polypeptides in the prodrug may form stable heterodimers through “knobs-into-holes” mutations. “Knobs-into-holes” mutations are made to promote the formation of the heterodimers of the antibody heavy chains and are commonly used to make bispecific antibodies (see, e.g., U.S. Pat. No. 8,642,745). For example, the Fc domain of the antibody may comprise a T366W mutation in the CH3 domain of the “knob chain” and T366S, L368A, and/or Y407V mutations in the CH3 domain of the “hole chain.” An additional interchain disulfide bridge between the CH3 domains can also be used, e.g., by introducing a Y349C mutation into the CH3 domain of the “knobs chain” and an E356C or S354C mutation into the CH3 domain of the “hole chain” (see, e.g., Merchant et al., Nature Biotech (1998) 16:677-81). In other embodiments, the antibody moiety may comprise Y349C and/or T366W mutations in one of the two CH3 domains, and E356C, T366S, L368A, and/or Y407V mutations in the other CH3 domain. In certain embodiments, the antibody moiety may comprise Y349C and/or T366W mutations in one of the two CH3 domains, and S354C (or E356C), T366S, L368A, and/or Y407V mutations in the other CH3 domain, with the additional Y349C mutation in one CH3 domain and the additional E356C or S354C mutation in the other CH3 domain, forming an interchain disulfide bridge (numbering always according to EU index of Kabat; Kabat et al., “Sequences of Proteins of Immunological Interest,” 5th ed., Public Health Service, National Institutes of Health, Bethesda, Md. (1991)). Other knobs-into-holes technologies, such as those described in EP1870459A1, can be used alternatively or additionally. Thus, another example of knobs-into-holes mutations for an antibody moiety is having R409D/K370E mutations in the CH3 domain of the “knob chain” and D399K/E357K mutations in the CH3 domain of the “hole chain” (EU numbering).
In some embodiments, the antigen-binding moiety in the prodrug is an antibody that comprises L234A and L235A (“LALA”) mutations in its Fc domain. The LALA mutations eliminate complement binding and fixation as well as Fcγ dependent ADCC (see, e.g., Hezareh et al., J. Virol. (2001) 75(24):12161-8). In further embodiments, the LALA mutations are present in the antibody moiety in addition to the knobs-into-holes mutations. In some embodiments, the antibody moiety in the prodrug further comprises G237A mutation in its Fc domain.
In some embodiments, the antigen-binding moiety is an antibody that comprises the M252Y/S254T/T256E (“YTE”) mutations in the Fc domain. The YTE mutations allow the simultaneous modulation of serum half-life, tissue distribution and activity of IgG1 (see Dall'Acqua et al., J Biol Chem. (2006) 281:23514-24; and Robbie et al., Antimicrob Agents Chemother. (2013) 57(12):6147-53). In further embodiments, the YTE mutations are present in the antibody in addition to the knobs-into-holes mutations. In particular embodiments, the antibody has YTE, LALA and knobs-into-holes mutations or any combination thereof.
In some embodiments, the antibody or antigen-binding fragment thereof binds to a receptor of a cytokine (except the receptor for IL-10 or TGF-β) or a receptor for a chemokine. In some embodiments, the antibody or antigen-binding fragment binds to an antigen on an immune cell, for examples, IL-1 receptor accessory protein (IL1RAP), IL-1 receptor (IL-1RI), a human IL-3 receptor, IL-4 receptor α chain (IL-4Rα), IL-5 receptor α chain (IL-5Rα), IL-6 receptor α chain (IL-6Rα), a human IL-9 receptor, a human IL-13 receptor, a human IL-17 receptor, a human IL-23 receptor, a human IL-31 receptor, a human IL-33 receptor, a receptor for thymic stromal lymphopoietin (TSLP), CD20, CD25, BCMA, CD40, CD80, CD86, mucosal addressin cell adhesion molecule 1 (MAdCAM-1), triggering receptors expressed on myeloid cells-1 (Trem-1), Colony-stimulating factor 1 receptor (CSF-1R), OX40, 4-1BB, TNF-alpha receptor 1 (TNFR-1), TNF-alpha receptor 1 (TNFR-2), a receptor for B lymphocyte stimulator (BLyS), and an Interferon-alpha receptor. In some embodiments, the antibody binds to a cytokine (except IL-10 and TGF-β). In some embodiments, the antibody or antigen-binding fragment thereof binds to and neutralizes a biological activity of a cytokine selected from IL-1α, IL-1(3, IL-4, IL-5, IL-6, IL-12, IL-13, IL-17, IL-23, IL-31, IL-33, tumor necrosis factor alpha (TNFα), and interferon alpha (IFNα), interferon gamma (IFNγ). In other embodiments, the antibody or antigen-binding fragment thereof binds to and neutralizes a biological activity of a cytokine selected from IL-1α, IL-1(3, IL-4, IL-5, IL-6, 11-12, IL-13, IL-17, IL-23, IL-31, IL-33, TNFα, and interferon alpha (IFNα), interferon gamma (IFNγ) or binds to and neutralizes a chemokine.
In some embodiments, the antigen-binding moiety comprises the six complementarity determining regions (CDRs) of dupilumab, benralizumab, tocilizumab, sarilumab, canakinumab, adalimumab, CDP-571, infliximab, rontalizumab, sifalimumab, olokizumab (CDP6038), elsilimomab, BMS-945429 (ALD518), sirukumab (CNTO 136), levilimab (BCD-089), siltuximab, secukinumab, ixekizumab, ustekinuma, guselkumab and tildrakizumab.
A number of CDR delineations are known in the art and are encompassed herein. A person of skill in the art can readily determine a CDR for a given delineation based on the sequence of the heavy or light chain variable region. The “Kabat” CDRs are based on sequence variability and are the most commonly used (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)). “Chothia” CDRs refer to the location of the structural loops (Chothia & Lesk, J. Mol. Biol. (1987) 196:901-917). The “AbM” CDRs represent a compromise between the Kabat CDRs and Chothia structural loops, and are used by Oxford Molecular's AbM antibody modeling software. The “Contact” CDRs are based on an analysis of the available complex crystal structures. The residues from each of these CDRs are noted below in Table 1, in reference to common antibody numbering schemes. Unless otherwise specified herein, amino acid numbers in antibodies refer to the Kabat numbering scheme as described in Kabat et al., supra, including when CDR delineations are made in reference to Kabat, Chothia, AbM, or Contact schemes. Using this numbering system, the actual linear amino acid sequence may contain fewer or additional amino acids corresponding to a shortening of, or insertion into, a framework region (FR) or CDR of the variable domain. For example, a heavy chain variable domain may include a single amino acid insert (residue 52a according to Kabat) after residue 52 of H2 and inserted residues (e.g., residues 82a, 82b, and 82c, etc. according to Kabat) after heavy chain FR residue 82. The Kabat numbering of residues may be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a “standard” Kabat numbered sequence.
In some embodiments, the CDRs are “extended CDRs,” and encompass a region that begins or terminates according to a different scheme. For example, an extended CDR can be as follows: L24-L36, L26-L34, or L26-L36 (VL-CDR1); L46-L52, L46-L56, or L50-L55 (VL-CDR2); L91-L97 (VL-CDR3); H47-H55, H47-H65, H50-H55, H53-H58, or H53-H65 (VH-CDR2); and/or H93-H102 (VH-CDR3).
In some embodiments, the antigen-binding moiety comprises one, two, three, or four antigen-binding domains. For example, the antigen-binding moiety is bispecific and binds to two different antigens selected from the group consisting of IL-1 receptor accessory protein (IL1RAP), IL-1 receptor (IL-1RI), a human IL-3 receptor, IL-4 receptor α chain (IL-4Rα), IL-5 receptor α chain (IL-5Rα), IL-6 receptor α chain (IL-6Rα), a human IL-9 receptor, a human IL-13 receptor, a human IL-17 receptor, a human IL-23 receptor, a human IL-31 receptor, a human IL-33 receptor, a receptor for thymic stromal lymphopoietin (TSLP), CD20, CD25, BCMA, CD40, CD80, CD86, mucosal addressin cell adhesion molecule 1 (MAdCAM-1), triggering receptors expressed on myeloid cells-1 (Trem-1), Colony-stimulating factor 1 receptor (CSF-1R), OX40, 4-1BB, TNF-alpha receptor 1 (TNFR-1), TNF-alpha receptor 1 (TNFR-2), a receptor for B lymphocyte stimulator (BLyS), and an Interferon-alpha receptor.
2. Other Domains of Carrier Moieties
The carrier moieties may also comprise other domains that are not antigen-binding. For example, an antibody Fc domain (e.g., a human IgG1, IgG2, IgG3, or IgG4 Fc), a polymer (e.g., PEG), an albumin (e.g., a human albumin) or a fragment thereof, or a nanoparticle can be used.
By way of example, the cytokine agonist polypeptide (e.g., IL-10 or TGF-β) and its antagonist may be fused to an antibody Fc domain, forming an Fc fusion protein. In some embodiments, the cytokine agonist polypeptide is fused (directly or through a peptide linker) to the C-terminus or N-terminus of one of the Fc domain polypeptide chains, and the cytokine mask is fused to the corresponding C-terminus or N-terminus of the other Fc domain polypeptide chain through a cleavable peptide linker, wherein the two Fc domain polypeptide chains contain mutations that allow the specific pairing of the two different Fc chains. In some embodiments, the Fc domain comprises the knobs-into-holes mutations described above. In further embodiments, the Fc domain also comprise the YTE and/or LALA mutations described above.
The carrier moiety of the prodrug may comprise an albumin (e.g., human serum albumin) or a fragment thereof. In some embodiments, the carrier moiety comprises an albumin fragment (e.g., a human serum albumin fragment) that is about 10 or more, 20 or more, 30 or more 40 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, 100 or more, 120 or more, 140 or more, 160 or more, 180 or more, 200 or more, 250 or more, 300 or more, 350 or more, 400 or more, 450 or more, 500 or more, or 550 or more amino acids in length. In some embodiments, the albumin fragment is between about 10 amino acids and about 584 amino acids in length (such as between about 10 and about 20, about 20 and about 40, about 40 and about 80, about 80 and about 160, about 160 and about 250, about 250 and about 350, about 350 and about 450, or about 450 and about 550 amino acids in length). In some embodiments, the albumin fragment includes the Sudlow I domain or a fragment thereof, or the Sudlow II domain or the fragment thereof.
In some embodiments, the carrier is an antibody Fc fragment. Fc is a dimeric molecule that has two N-terminals and two C-terminals. In some embodiments, the cytokine moiety can be fused to one Fc polypeptide in a dimeric Fc fragment, and the masking moieties can be fused to the 2nd Fc polypeptide. In a preferred embodiment, both the cytokine moiety and the masking moiety are fused to the C-terminal of each polypeptide chain of the dimeric Fc fragment. In some embodiments, both the cytokine moiety and the masking moieties are fused to the N-terminal of each polypeptide chain of the dimeric Fc fragment.
D. Linker Components of the Prodrugs
The moieties of the prodrugs disclosed herein may be fused to each other through one or more peptides linkers (e.g., non-cleavable linker or cleavable linker). The cytokine moiety may be fused to the carrier moiety with or without a peptide linker. The peptide linker may be non-cleavable and may be selected from GGGGS (SEQ ID NO: 117), GGGGSGGGGS (SEQ ID NO: 118), GGGGSGGGGSGGGGS (SEQ ID NO: 119), and GGGGSGGGGSAAGGGGSGGGGS (SEQ ID NO: 120).
The cleavable linker may contain one or more (e.g., two or three) cleavable moieties (CM). Each CM may be a substrate for an enzyme or protease selected from legumain, plasmin, TMPRSS-3/4, MMP2, MMP3, MMP9, MT1-MMP, cathepsin, caspase, human neutrophil elastase, beta-secretase, uPA, EOS, and PSA. Examples of cleavable linkers include, without limitation, those comprising an amino acid sequence selected from SEQ ID NOs: 75-95. The peptide linker may be a cleavable peptide linker comprising PYAYWMR (SEQ ID NO: 76). In some embodiments, the cleavable linker is no more than 10 amino acids, or no more than 8 amino acids, or no more than 6 amino acids in length.
Pharmaceutical compositions of the prodrugs or chimeric molecules are prepared by mixing the presently disclosed prodrugs or chimeric molecules having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (see Osol, A. Ed. Remington's Pharmaceutical Sciences 16th edition (1980)), in the form of lyophilized formulations or aqueous solutions. Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as polyethylene glycol (PEG).
Buffers are used to control the pH in a range which optimizes the therapeutic effectiveness, especially if stability is pH dependent. Buffers are preferably present at concentrations ranging from about 50 mM to about 250 mM. Suitable buffering agents for use with the present invention include both organic and inorganic acids and salts thereof, such as citrate, phosphate, succinate, tartrate, fumarate, gluconate, oxalate, lactate, acetate. Additionally, buffers may comprise histidine and trimethylamine salts such as Tris.
Preservatives are added to retard microbial growth, and are typically present in a range from 0.2%-1.0% (w/v). Suitable preservatives for use with the present invention include octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium halides (e.g., chloride, bromide, iodide), benzethonium chloride; thimerosal, phenol, butyl, or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol, 3-pentanol, and m-cresol.
Tonicity agents, sometimes known as “stabilizers” are present to adjust or maintain the tonicity of liquid in a composition. When used with large, charged biomolecules such as proteins and antibodies, they are often termed “stabilizers” because they can interact with the charged groups of the amino acid side chains, thereby lessening the potential for inter- and intra-molecular interactions. Tonicity agents can be present in any amount between 0.1% to 25% by weight, or more preferably between 1% to 5% by weight, taking into account the relative amounts of the other ingredients. Preferred tonicity agents include polyhydric sugar alcohols, preferably trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol, and mannitol.
Non-ionic surfactants or detergents (also known as “wetting agents”) are present to help solubilize the therapeutic agent as well as to protect the therapeutic protein against agitation-induced aggregation, which also permits the formulation to be exposed to shear surface stress without causing denaturation of the active therapeutic protein or antibody. Non-ionic surfactants are present in a range of about 0.05 mg/ml to about 1.0 mg/ml, preferably about 0.07 mg/ml to about 0.2 mg/ml.
Suitable non-ionic surfactants include polysorbates (20, 40, 60, 65, 80, etc.), polyoxamers (184, 188, etc.), PLURONIC® polyols, TRITON®, polyoxyethylene sorbitan monoethers (TWEEN®-20, TWEEN®-80, etc.), lauromacrogol 400, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and 60, glycerol monostearate, sucrose fatty acid ester, methyl cellulose and carboxymethyl cellulose. Anionic detergents that can be used include sodium lauryl sulfate, dioctyle sodium sulfosuccinate and dioctyl sodium sulfonate. Cationic detergents include benzalkonium chloride or benzethonium chloride.
The choice of pharmaceutical carrier, excipient or diluent may be selected with regard to the intended route of administration and standard pharmaceutical practice. Pharmaceutical compositions may comprise as—or in addition to—the carrier, excipient, or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s) or solubilizing agent(s).
There may be different composition/formulation requirements dependent on the different delivery systems. By way of example, pharmaceutical compositions useful in the present invention may be formulated to be administered using a mini-pump or by a mucosal route, for example, as a nasal spray or aerosol for inhalation or ingestible solution, or parenterally in which the composition is formulated by an injectable form, for delivery, by, for example, an intravenous, intramuscular, or subcutaneous route. Alternatively, the formulation may be designed to be administered by a number of routes. In some embodiments, said formulation is administrated topically.
In some embodiments, an antibody or protein formulation is a lyophilized formulation. In some embodiments, an antibody or protein formulation is an aqueous formulation.
In some embodiments, the pharmaceutical composition is a combination pharmaceutical composition, which comprises a chimeric molecule or prodrug of the present invention, a pharmaceutically acceptable excipient, and a second active ingredient selected from a different cytokine or its fusion molecule, an antibody against TNFα, an antibody against IL-6, an antibody against IL-17, an antibody against IL-23, and an IL-2 mutein which selectively stimulate and activate Treg cells.
The presently disclosed chimeric molecules or prodrugs can be used to treat a disease, depending on the antigen bound by the antigen-binding domain. In some embodiments, the chimeric molecule or prodrugs disclosed herein are used to treat a disease such as an autoimmune disease or an inflammation disease.
In some embodiments, a method of treating a disease in a subject comprises administering to the subject an effective amount of the presently disclosed chimeric molecule or prodrugs.
In some embodiments, the autoimmune disease or inflammation disease or condition is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, osteoarthritis, psoriasis, graft vs host disease (GvHD), lupus (e.g., SLE), a neurodegeneration disease (e.g., Alzheimer's disease), an inflammatory bowel disease, ulcerative colitis, Crohn's disease, NASH, atherosclerosis, and systemic sclerosis.
Generally, dosages and routes of administration of the present pharmaceutical compositions are determined according to the size and condition of the subject, according to standard pharmaceutical practice. In some embodiments, the pharmaceutical composition is administered to a subject through any route, including orally, transdermally, by inhalation, intravenously, intra-arterially, intramuscularly, direct application to a wound site, application to a surgical site, intraperitoneally, by suppository, subcutaneously, intradermally, transcutaneously, topically, by nebulization, intrapleurally, intraventricularly, intra-articularly, intraocularly, or intraspinally. In some embodiments, the composition is administered to a subject intravenously.
In some embodiments, the prodrug is administered to a subject in need a single dose or a repeated dose. In some embodiments, the doses are given to a subject once per day, twice per day, three times per day, or four or more times per day. In some embodiments, about 1 or more (such as about 2, 3, 4, 5, 6, or 7 or more) doses are given in a week. In some embodiments, the antibody fusion molecule conjugated to the drug is administered weekly, once every 2 weeks, once every 3 weeks, once every 4 weeks, weekly for two weeks out of 3 weeks, or weekly for 3 weeks out of 4 weeks. In some embodiments, multiple doses are given over the course of days, weeks, months, or years. In some embodiments, a course of treatment is about 1 or more doses (such as about 2, 2, 3, 4, 5, 7, 10, 15, or 20 or more doses).
In some embodiments, the chimeric molecule or prodrug is administered to a subject in combination with a second pharmaceutical composition, wherein the second pharmaceutical composition comprises an active ingredient selected from another cytokine or its fusion molecule such as an IL-2 mutein which selectively stimulate Treg cells, an antibody against TNFα, an antibody against IL-1, an antibody against IFN-γ, an antibody against IFNα, an antibody against IL-6, an antibody against IL-17, and an antibody against IL-23.
The presently disclosed prodrugs or chimeric molecules can be produced using recombinant DNA methods. Nucleic acid molecules encoding the polypeptide or the fusion polypeptide of the prodrug can be isolated and inserted into one or more vectors for further cloning and/or expression in a host cell. Such nucleic acid molecules may be readily isolated and sequenced using conventional methods. Suitable host cells for cloning or expression of fusion polypeptide vectors include prokaryotic cells or eukaryotic cells. Exemplary host cells include Chinese Hamster Ovary (CHO) cells or human embryonic kidney cells (e.g., HEK293).
Expression host cells express the antibody fusion molecule. After an expression period, the host cells can be lysed and the prodrug or antibody fusion molecule can be purified. Exemplary purification methods include liquid chromatography, such as ion exchange chromatography, affinity chromatography (such as Protein A affinity chromatography), or size exclusion chromatography.
It is understood that although aspects of the present specification are highlighted by referring to specific embodiments, one skilled in the art will readily appreciate that these disclosed embodiments are only illustrative of the principles of the subject matter disclosed herein. Therefore, it should be understood that the disclosed subject matter is not intended to be limited to a particular compound, composition, article, or method, unless expressly stated as such. In addition, those of ordinary skill in the art will recognize that certain changes, modification, permutations, alterations, additions, subtractions, and sub-combinations thereof can be made in accordance with the teachings herein without departing from the spirit of the present specification.
Unless otherwise defined herein, scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. Exemplary methods and materials are described below, although methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure. In case of conflict, the present specification, including definitions, will control. Generally, nomenclature used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics, analytical chemistry, synthetic organic chemistry, medicinal and pharmaceutical chemistry, and protein and nucleic acid chemistry and hybridization described herein are those well-known and commonly used in the art. Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Throughout this specification and embodiments, the words “have” and “comprise,” or variations such as “has,” “having,” “comprises,” or “comprising,” will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers. It is understood that aspects and variations of the invention described herein include “consisting” and/or “consisting essentially of” aspects and variations. All publications and other references mentioned herein are incorporated by reference in their entirety. Although a number of documents are cited herein, this citation does not constitute an admission that any of these documents forms part of the common general knowledge in the art.
In order that this invention may be better understood, the following exemplary embodiments are set forth. These embodiments are for purposes of illustration only and are not to be construed as limiting the scope of the invention in any manner.
1. A chimeric molecule which modulates a function of an immune cell and is useful to treat a patient with an autoimmune disease or an inflammatory condition, comprising:
Expression plasmids were co-transfected into 6×10 6 cell/ml freestyle ExpiCHO™ cells at 1 μg/ml using ExpiFectamine™ CHO Transfection kit (Gibco). For the IL-10 prodrug molecules of two or more polypeptide chains, the ratios of the various chains were tested to achieve good transient expression titers.
The purifications of the proteins of the IL-10 prodrugs were carried out using Protein A affinity chromatography. Additional purification steps were carried out using additional chromatography and filtration steps. For example, chromatography steps with resins such as Capto™ MMC ImpRes, Capto™ Adhere, Capto™ SP, and/or Q Sepharose FF can be used for further purification of the prodrugs. For the prodrug IL-10-J, it was further purified by Capto™ MMC Impres after the Protein A Affinity Chromatography. Its purity was analyzed by SEC-HPLC (
SEC-HPLC was carried out using an Agilent 1100 Series of HPLC system with a TSKgel® G3000SWXL column (7.8 mmIDX 30 cm, 5 μm particle size) ordered from Tosoh Bioscience. A sample of up to 10011.1 was loaded. The column was run with a buffer containing 200 mM K3PO4, 250 mM KCl, pH 6.5. The flow rate was 0.5 ml/min. The column was run at room temperature. The protein elution was monitored both at 220 nm and 280 nm.
One μg of the protease, human MMP-2 (R&D systems), human MMP-9 (R&D systems), mouse MMP-2 (R&D systems), or mouse MMP-9 (R&D systems) was added to 50 of the precursor protein, and incubated at 37° C. overnight.
Interleukin-10 binding to its receptor causes oligomerization of the IL-10Rα chain and IL-10Rβ chain. This allows phosphorylation of JAK1 and TyK2 resulting in activation of STAT3. Functional activity of IL-10 was measured using a secreted alkaline phosphatase reporter cell line (HEK-Blue™ IL-10, InvivoGen). This reporter cell line consists of HEK293 cells stably transfected with the IL10Rα and IL10Rβ chains, human STAT3 and a secreted alkaline phosphatase (SEAP) reporter. The reporter gene is under control of the IFN-β minimal promoter fused to AP1 and STAT3 binding sites. The cell line is also knockout for the expression of human IFNAR2 and human IL-6R to prevent STAT3 signaling from other cytokines known to activate STAT3. Culturing HEK-Blue™ IL-10 cells with IL-10 activates JAK1/STAT3 resulting in the production of SEAP in the culture supernatant, which is quantitated using Quanti-Blue™ Solution (InvivoGen). Test articles were serially diluted in 50 μL/well in 96-well tissue culture plates. HEK-Blue™ IL-10 cells were added at 30,000 cells/well/50 μL. Cultures were incubated overnight at 37° C., and 20 μL of culture supernatant was transferred to an ELISA plate and 180 μL of Quanti-Blue™ Solution is added. Plates were incubated at 37° C. for 1 hour, and absorbance was measured with a spectrophotometer at 450 nm.
The prodrugs of
The above non-limiting examples are provided for illustrative purposes only in order to facilitate a more complete understanding of the disclosed subject matter. These examples should not be construed to limit any of the embodiments described in the present specification, including those pertaining to the antibodies, pharmaceutical compositions, or methods and uses for treating an autoimmune disease or inflammatory condition.
MGVLLTQRTL LSLVLALLFP SMASMA
MHVA QPAVVLASSR GIASFVCEYA SPGKATEVRV
GPLGVR (SEQ ID NO: 77)
PLGMWSR (SEQ ID NO: 78)
PLGLWAR (SEQ ID NO: 79)
PQGIAGQR (SEQ ID NO: 80)
PLGLAG (SEQ ID NO: 81)
LALGPR (SEQ ID NO: 82)
GGPLGMLSQS (SEQ ID NO: 83)
GGGGRRGGS (SEQ ID NO: 84)
TGRGPSWV (SEQ ID NO: 85)
SARGPSRW (SEQ ID NO: 86)
TARGPSFK (SEQ ID NO: 87)
TARGPSW (SEQ ID NO: 88)
GGWHTGRN (SEQ ID NO: 89)
HTGRSGAL (SEQ ID NO: 90)
PLTGRSGG (SEQ ID NO: 91)
LTGRSGA (SEQ ID NO: 92)
RQARVVNG (SEQ ID NO: 93)
VHMPLGFLGP RQARVVNA (SEQ ID NO: 94).
MGVLLTQRTL LSLVLALLFP SMASM
AMHVA QPAVVLASSR GIASFVCEYA SPGKATEVRV
MGVLLTQRTL LSLVLALLFP SMASMA
MHVA QPAVVLASSR GIASFVCEYA SPGKATEVRV
MGVLLTQRTL LSLVLALLFP SMASMA
MHVA QPAVVLASSR GIASFVCEYA SPGKATEVRV
MGVLLTQRTL LSLVLALLFP SMASMA
MHVA QPAVVLASSR GIASFVCEYA SPGKATEVRV
MGVLLTQRTL LSLVLALLFP SMASMA
MHVA QPAVVLASSR GIASFVCEYA SPGKATEVRV
MGVLLTQRTL LSLVLALLFP SMASMA
MHVA QPAVVLASSR GIASFVCEYA SPGKATEVRV
MDMRVPAQLL GLLLLWLPGA KCDIVLTQSP DSLAVSLGER ATINCRASES VDTEDYSELH
MGVKVLFALI CIAVAEAEVQ LVESGGGLVQ PGGSLKLSCA ASGFTESTYA MHWVRQASGK
MGVKVLFALI CIAVAEAEVQ LVESGGGLVQ PGGSLKLSCA ASGFTFSTYA MHWVRQASGK
MGVKVLFALI CIAVAEAEVQ LVESGGGLVQ PGGSLKLSCA ASGFTESTYA MHWVRQASGK
MGVKVLFALI CIAVAEAEVQ LVESGGGLVQ PGGSLKLSCA ASGFTESTYA MHWVRQASGK
MGVKVLFALI CIAVAEAEVQ LVESGGGLVQ PGGSLKLSCA ASGFTESTYA MHWVRQASGK
MGVKVLFALI CIAVAEAQVQ LVQSGAEVKK PGASVKVSCK ASGYTFTSYG INWVRQAPGQ
DIVMTQTPLS LSVTPGQPAS ISCKSSQSLL HTDGTTYLYW YLQKPGQPPQ LLIYEVSNRE
SGVPDRESGS GSGTDFTLKI SRVEAEDVGI YYCMQNIQLP WTFGQGTKVE IKRTVAAPSV
The present application claims priority from U.S. Provisional Application No. 63/143,954, filed on Feb. 1, 2021, the contents of which are incorporated herein by reference in their entirety.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2022/014801 | 2/1/2022 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63143954 | Feb 2021 | US |
